Gut microbiota-dependent phenylacetylglutamine in cardiovascular disease:current knowledge and new insights  

作　　者：Yaonan Song Haoran Wei Zhitong Zhou Huiqing Wang Weijian Hang Junfang Wu Dao Wen Wang 

机构地区：[1]Division of Cardiology,Department of Internal Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China [2]Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders,Wuhan,430030,China

出　　处：《Frontiers of Medicine》2024年第1期31-45,共15页医学前沿（英文版）

基　　金：supported by the National Key Research and Development Program of China(No.2022YFC3400700);National Natural Science Foundation of China(Nos.31971358,82370397,U22A20266,and 82100402);Hubei Provincial Key Research and Developmental Program(No.2022BCA037);Hubei Provincial Natural Science Foundation of China(Nos.2017CFB536 and 2022CFB201).

摘　　要：Phenylacetylglutamine(PAGln)is an amino acid derivate that comes from the amino acid phenylalanine.There are increasing studies showing that the level of PAGln is associated with the risk of different cardiovascular diseases.In this review,we discussed the metabolic pathway of PAGln production and the quantitative measurement methods of PAGln.We summarized the epidemiological evidence to show the role of PAGln in diagnostic and prognostic value in several cardiovascular diseases,such as heart failure,coronary heart disease/atherosclerosis,and cardiac arrhythmia.The underlying mechanism of PAGln is now considered to be related to the thrombotic potential of platelets via adrenergic receptors.Besides,other possible mechanisms such as inflammatory response and oxidative stress could also be induced by PAGln.Moreover,since PAGln is produced across different organs including the intestine,liver,and kidney,the cross-talk among multiple organs focused on the function of this uremic toxic metabolite.Finally,the prognostic value of PAGln compared to the classical biomarker was discussed and we also highlighted important gaps in knowledge and areas requiring future investigation of PAGln in cardiovascular diseases.

关 键 词：PAGln cardiovascular disease gut microbiota uremic metabolite BIOMARKER 

分 类 号：R574[医药卫生—消化系统]